Skip to main content
OpenTrials
Completed

NCT Number: NCT00261131

Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy

The study proposes to determine if injections of BTX-A to the hamstring muscles result in measurable physiologic changes not observed with normal saline injections in children with spastic diplegic cerebral palsy who walk with a flexed-knee gait pattern.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study proposes to: (1) to determine if injections of BTX-A to the hamstring muscles result in measurable physiologic (body structure and body function) changes not observed with normal saline injections, in children with spastic diplegic CP who walk with a flexed-knee gait pattern; (2) to assess whether physiologic changes translate into functional (activity and participation) improvements; (3) to evaluate family's perception of change in function, activity, participation, and quality of life.

This study will demonstrate if BTX-A injected into overactive hamstring muscles of children with spastic cerebral palsy (CP) and a flexed-knee walking pattern has measurable effects across the spectrum of dimensions of disablement of the International Classification of Functioning, Disability, and Health (ICF). It is a multi-center, prospective, randomized, double-blind trial comparing results of injection of BTX- A and placebo saline in controls, into overactive hamstring muscles, using multiple outcomes measures. Temporal-spatial gait parameters, instrumented 3DGA kinematics, passive ROM, spasticity measurement with both Ashworth and Tardieu scales, muscle strength/control, Gross Motor Function Measurement (GMFM), Pediatric Outcomes Data Collection Instrument (PODCI), Gillette Functional Assessment Questionnaire (FAQ), 6-Minute Walk Test, and Goal Attainment Scale (GAS), assessing all ICF domains, will be collected at baseline and at 1 month, 3 months, and 6 months post-injection. Power analysis demonstrates the need to randomize 250 children (125 with BTX-A, 125 with saline), allowing for attrition. Nine participating hospitals will contribute patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Spastic cerebral palsy;
  • Bilateral lower extremity involvement;
  • Spasticity present in the hamstrings;
  • Flexed knee gait >15 degrees by observation (OGS);
  • Age between 3 and 18 years old; (
  • GMFCS Level I to Level IV; (
  • Able to walk a minimum of 4 complete steps without resting with and without braces/shoes a minimum of 3 times;
  • Able to follow simple commands;
  • Cooperative with physicians and therapist;
  • Able to tolerate application of equipment to the skin.

Exclusion criteria

  • Rhizotomy surgery within the last 1 year;
  • Lower extremity surgical procedures (soft tissue or bony) within the past 1 year;
  • Currently implanted and operating Intrathecal Baclofen Pump (oral baclofen OK);
  • Lower extremity BTX-A injections within the past 6 months;
  • Multilevel BTX-A injections;
  • Gait trainer reliance;
  • Serial casting 3 months prior to or during study protocol.

Treatment and study plan

Botulinum toxin A

Drug

Primary outcomes

  1. 3DGA Kinematics

  2. Passive Range of Motion

  3. Spasticity Measurement with AShworth and Tardieu Scales

  4. Muscle Strength and Control

Secondary outcomes

  1. Gross Motor Function Measurement (GMFM)

  2. Pediatric Outcomes Data Collection Instrument (PODCI)

  3. Gillette Functional Assessment Questionnaire (GFAQ)

  4. 6-Minute Walk Test

  5. Goal Attainment Scale (GAS)

Sponsors and collaborators

Lead sponsor

Shriners Hospitals for Children

Other

Collaborators

  • University of Virginia
  • Washington University School of Medicine

Registry information

Official study title

Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial

Important dates

Study start
2006
Study completion
2007
First posted
Dec 2, 2005
Registry last updated
Feb 5, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.